Serina Therapeutics (SER) Income from Discontinued Operations (2020 - 2021)
Serina Therapeutics' (SER) quarterly Income from Discontinued Operations came in at -$103000.0 in Q1 2021, up 45.5% year-over-year from -$70789.1 in Q1 2020, and up 47.98% quarter-over-quarter from -$198000.0 in Q4 2020.
Powered by 
Analysis
Serina Therapeutics (SER) Income from Discontinued Operations (2020 - 2021) Analysis & Trends
Serina Therapeutics has disclosed Income from Discontinued Operations across 2 years of filings, most recently posting -$103000.0 for Q1 2021.
- In Q1 2021, Income from Discontinued Operations rose 45.5% year-over-year to -$103000.0; the TTM figure through Dec 2021 stood at -$103000.0 (up 85.83% YoY), while the FY2021 annual figure was -$103000.0, up 85.83% from the prior year.
- Income from Discontinued Operations came in at -$103000.0 for Q1 2021 at Serina Therapeutics, up from -$198000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of -$41000.0 in Q3 2020 to a low of -$299000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Serina Therapeutics | 40.47 Mn | 17.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | -103,000.00 |
| Dec 31, 2020 | -198,000.00 |
| Sep 30, 2020 | -41,000.00 |
| Jun 30, 2020 | -299,000.00 |
| Mar 31, 2020 | -189,000.00 |